Pharming Group (OTCMKTS:PHGUF) Announces Quarterly Earnings Results

Pharming Group (OTCMKTS:PHGUF) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share for the quarter, Zacks reports. Pharming Group had a net margin of 3.30% and a return on equity of 4.68%. The company had revenue of $72.45 million during the quarter, compared to the consensus estimate of $92.06 million.

Pharming Group Stock Performance

OTCMKTS PHGUF remained flat at $1.25 on Friday. The stock has a market cap of $836.96 million, a PE ratio of 62.39 and a beta of 0.55. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.59 and a quick ratio of 2.03. Pharming Group has a twelve month low of $0.96 and a twelve month high of $2.17. The business has a 50 day simple moving average of $1.60 and a 200 day simple moving average of $1.65.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.